Abstract: IGF-1 is administered to a patient for the treatment or prevention of atrophy of the gut mucosa.

Abstract: The present invention relates to formulations and methods for treating wounds utilizing these formulations. The formulations according to the present invention are useful for treating wounds by accelerating wound healing. These formulations comprise an effective amount of a serum free cellular nutrient medium in combination with an effective amount of at least one cellular growth stimulating compound, e.g. a natural anabolic hormone or transforming growth factor.

Abstract: EGF (Epidermal Growth Factor)-containing pharmaceutical composition and method for the treatment of bronchopulmonary pathologies accompanied by lesions of the bronchial epithelium utilising EGF.

Abstract: Garlic essence is produced by extracting garlic with ethanol and deodorized with phytic acid, added either during or after the extracting step. The garlic essence exhibits outstanding antibacterial action when added to or sprayed onto foods. It is used alone or in combination with .epsilon.-polylysine in the amount of 1-256 .mu.g/ml.

Abstract: A process for purifying IGF-I from variants of IGF-I is provided. In this process a mixture containing IGF-I and its variants is loaded onto a reversed-phase liquid chromatography column and the IGF-I is eluted from the column with a buffer at a pH of about 6-8. The buffer contains an alcoholic or polar aprotic solvent at a concentration of about 20-30% (v/v). This process can be preceded by a hydrophobic-interaction chromatography step.

Abstract: A method is disclosed which comprises a method for reducing atrophy in at least one striated skeletal muscle of an individual, comprising administering a therapeutically effective amount of Insulin-like Growth Factor-I (IGF-I) to said individual.

Abstract: A method of enhancing the growth of a bird is described. The method comprises (a) administering a compound selected from the group consisting of IGF-1, IGF-2 and active analogs thereof to a bird in ovo; then (b) incubating the bird to hatch; and then (c) growing the bird for at least three weeks after hatch. The compound is administered in ovo in an amount sufficient to enhance the growth of the bird at least three weeks after hatch. Preferred birds for practicing the present invention are chickens, and preferred compounds for practicing the present invention are IGF-1 and analogs thereof. The use of IGF-1, IGF-2 and active analogs thereof for the preparation of a medicament for administration to birds in ovo to ehance the growth of the bird at least three weeks after hatch is also disclosed, along with the pharmaceutical formulations so prepared.

Abstract: A substantially pure heterotrimeric laminin variant comprising the structure M-X-B2, wherein M is the M polypeptide of merosin; X is selected from the group consisting of the B1 chain of laminin and S-laminin; and B2 is the B2 chain of laminin.

Abstract: A method of sorting living cells based on DNA content. Mammalian sperm subpopulations enriched in X- or Y-sperm. X- and Y-enriched sperm-plasma-membrane vesicles. Substantially pure sex-associated membrane (SAM) proteins. Antibodies binding to X- or Y-SAM proteins, essentially free of antibodies binding to Y- or X-SAM proteins respectively, or to the H-Y antigen. Semen samples enriched for X- or Y-sperm. Methods for increasing the probability that offspring will be male or female comprising the step of allowing as sperm from an enriched semen sample to fertilize an ovum. Methods for increasing the probability that offspring will be male or female comprising the step of immunizing a female with X- or Y-SAM proteins. Methods of decreasing fertility comprising the step of immunizing a female with both X- and Y-sperm. Methods of increasing the probability that mammalian offspring will carry a gene for a particular sex-chromosome linked trait.

Abstract: A novel human hepatokine, referred to hereinafter as HPX, has been isolated and purified from human fetal hepatocytes. HPX has a molecular weight of approximately 15 kD, a pI of about 6, and has been found to promote hepatocyte growth activity in vitro and in vivo.

Abstract: Hexapeptides of formula (I) deriving from aglucoteicoplanin and their salts with acids and bases as well as their inner salts wherein R is hydrogen or a protecting ##STR1## group of the amino function. The products of formula (I), wherein R is hydrogen, possess antimicrobial activity in particular against coagulase-negative strains and some S. aureus and S. epidermidis strains which have low sensitivity toward teicoplanin. The hexapeptides are produced by reductive cleavage of aglucoteicoplanin with alkali metal borohydrides in the presence of a hydroalcoholic mixture as solvent.

Abstract: Utilization of a growth factor as active principle of a slimming and lipolytic composition and its utilization in a treatment method particularly in the process for improving the aesthetic aspect of the skin. The slimming composition may also contain the growth factor in association with a lipolytic substance such as caffine.

Abstract: A method for the healing of wounds caused by corneal injury as the result of, for example, corneal ulcer, corneal epithelial defect, keratitis, xerophthalmia, which comprises locally administering to a patient in need thereof an effective wound healing amount of interleukin-6, either alone, or in combination with one or more pharmaceutically acceptable ophthalmic excipients.

Abstract: The present invention relates to a process for manufacturing a composition highly containing .alpha.-lactalbmin. This process comprises adjusting, to pH of 2-4 or 5 or higher, cheese whey, acid casein whey or rennet casein whey; contacting the whey with an ion exchanger, to produce an exchanger-passed solution; and then, concentrating and/or desalting the exchanger-passed solution, if necessary after the exchanger-passed solution is adjusted to a pH of 4 or lower. According to the present process, it is possible to efficiently produce a high .alpha.-lactalumin content composition at low cost and in a simple and easy manner on an industrial scale. The resultant high .alpha.-lactalumin content composition can be used for food materials and medical materials.

Abstract: A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.

Abstract: The invention relates to methods for stabilizing human interferon, including pharmaceutical compositions useful in topical applications for the treatment of disorders such as Condyloma acuminata. Amine stabilizing agents such as primary aliphatic amines and anionic stabilizing agents such as lithium organo sulfates protect human interferons from degradation and provide enhanced storage stability. These stabilizing agents containing interferon can be added to appropriate pharmaceutical carriers for topical applications. The topical products also exhibit enhanced storage stability.

Abstract: The invention relates to a pharmaceutical composition for oral administration containing cyclosporin A and/or cyclosporin G as active ingredient, which possess advantageous absorption characteristics, and to a process for preparing this composition. The composition according to the invention comprises 1 part by mass of one or more cyclosporin(s) dissolved in 4 to 50 parts by volume of propylene glycol, 0 to 25 parts by volume of ethanol and 0.0 to 5 parts by mass of a polyoxyethylene/polyoxypropylene block polymer in homogenized state. Based on examinations carried out at 100.degree. C., the stability of solutions prepared according to the invention does not differ from that of the commercially available Sandimmun oral solution.

Abstract: Thrombin inhibitors represented by the formula ##STR1## as provided wherein A(C.dbd.O)-- is, inter alia, phenylglycyl, cyclohexylglycyl, cyclohexenylglycyl, thienylglycyl or naphthylglycyl, wherein the .alpha.-amino group is preferably substituted by alkyl e.g. methyl or an alkoxycarbonyl, cycloalkoxycarbonyl or arylkoxycarbonyl group e.g. t-butyloxycarbonyl. A(C.dbd.O)-- also represents an .alpha.-substituted acetyl group such as .alpha.-methoxyphenylacetyl; or a bicyclic group such as a tetrahydroisoquinolin-1- or 3-carbonyl group; a perhydroisoquinolin -1- or -3-carbonyl group; or a 1-amino or (substituted amino) cycloalkylcarbonyl group such as 1-aminocyclohexylcarbonyl. Also provided are a method for inhibiting the formation of blood clots in man and animals by administering a thrombin inhibitor of the above formula and pharmaceutical formulations useful in the method.

Abstract: High concentration collagen compositions having improved persistence when administered for soft tissue augmentation are prepared from both cross-linked and non-cross-linked collagen starting materials. Suspensions of the starting materials are subjected to vigorous mechanical disruption to reduce the average collagen fiber size to below a threshold level which enhances the injectability of the composition. Thus, both enhanced injectability and enhanced persistence may be achieved using the same formulations.

Abstract: TGF.beta. is used to increase the numbers of stem cells in a subject's peripheral blood. Then the subject's blood is drawn and the stem cells removed. After myelosuppressive therapy is administered to the subject, the stem cells are administered to the subject. An alternate method provides for TGF.beta. administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed; after a recipient subject receives myelosuppressive therapy, the stem cells are administered to the recipient subject.